Biggest News Aggregation in the World
📰 Andy Plump News

Andy Plump News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Andy Plump. Real-time updates on events, politics, business and more.

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

− The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With TAK-279 Achieving At Least an ACR 20 Response Compared to 29.2% in the Placebo Group at Week 12 1 − TAK-279...
United States San Diego New Orleans United Kingdom Alan Kivitz Greenwood Carriero

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q2 2023 Earnings Call Transcript

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q2 2023 Earnings Call Transcript October 27, 2023 Christopher O’Reilly: Thank you very much for joining us out of your busy schedule today for the earnings call for Second Quarter Fiscal 2023 with Takeda Pharmaceutical Company Limited. I am going to be the moderator today O’Reilly, the Head of IR. […]
United States Christophe Weber Ramona Sequeira Julie Kim Citi Yamaguchi San Global Portfolio Division
Source: yahoo.com

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

− Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20 Response Compared to Placebo at Week 121 − Based on the...
United States New Orleans Greenwood Carriero American Academy Of Dermatology Annual Meeting Society For Investigative Dermatology Annual Meeting Takeda Pharmaceutical Company Limited

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK279 a Highly Selective Oral TYK2 Inhibitor for the Treatment of Active Psoriatic Arthritis

Takeda TSE4502NYSETAK today announced positive topline results from its randomized doubleblind placebocontrolled multipledose Phase 2b trial evaluating TAK279 an investigational oral allosteric tyrosine kinase 2 TYK2 inhibitor with next generation selectivity in people with active psoriatic arthritis.
New Orleans United States Mark Dole Jun Saito Greenwood Carriero Takeda Pharmaceuticals

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science